The regulatory green light stems from the BRAVE-AA-PEDS trial, the first Phase 3 study specifically targeting pediatric patients with this condition. Participants in the study, who had lived with the disease for a mean of 6.4 years and showed complete scalp hair loss at baseline, demonstrated substantial improvement after 36 weeks of treatment. Among those receiving the 4 mg dose, 42% achieved 80% or more scalp hair coverage, compared to 5% in the placebo group.

Brittany Craiglow, an adjunct associate professor of dermatology at the Yale School of Medicine, noted that early-onset disease can be particularly aggressive and challenging to manage. She emphasized that the study data provides clinicians and families with necessary evidence to make informed decisions regarding advanced therapies. While the drug offers a new option for a demographic with historically limited choices, the FDA label maintains a boxed warning for serious risks, including infections, malignancy, and major cardiovascular events, consistent with the profile seen in adult patients.